Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing the closing of its senior notes offering on May 18, 2020. The company successfully raised approximately $1.68 billion in net proceeds from the sale of its 1.900% Senior Notes due 2025 and 2.650% Senior Notes due 2030. This debt issuance was executed under the company's existing shelf registration statement and involved a customary underwriting agreement with several financial institutions. The primary use of the proceeds is to refinance existing debt. Specifically, Boston Scientific plans to use the funds to pay down $450 million of its revolving credit facility, as well as portions of its pre-payable bank debt, including $750 million from its term loan facility maturing in February 2021 and $500 million from its term loan facility maturing in April 2021. This move indicates a strategic debt management strategy, potentially optimizing the company's capital structure and managing upcoming maturities.
Key Highlights
- 1Boston Scientific closed a senior notes offering on May 18, 2020, raising approximately $1.68 billion in net proceeds.
- 2The offering consisted of $500 million of 1.900% Senior Notes due 2025 and $1.2 billion of 2.650% Senior Notes due 2030.
- 3The proceeds will be used primarily to refinance existing debt, including its revolving credit facility and term loans.
- 4This debt refinancing includes paying down $450 million under its revolving credit facility.
- 5A significant portion of the proceeds will address upcoming term loan maturities: $750 million of the February 2021 facility and $500 million of the April 2021 facility.
- 6The transaction was executed via an Underwriting Agreement with major financial institutions acting as representatives for the underwriters.
- 7The company is utilizing its shelf registration statement on Form S-3 for this debt issuance.